What patent does Kisqali (ribociclib) have, and what does it cover?
Kisqali is the brand name for ribociclib. The key IP around Kisqali typically centers on composition-of-matter (the drug itself) and specific formulations or additional claims tied to how ribociclib is made and used. The exact active patents and their remaining term depend on the country (e.g., US vs. EU) and the specific jurisdiction’s patent family and adjustments.
When does the Kisqali patent expire (and why do dates differ)?
Patent expiration can differ by market because of:
- Different patent families in different countries
- Patent term adjustments (in the US)
- Later-filed “secondary” patents (formulations, methods, dosing regimens)
- Potential regulatory exclusivity that can delay generic/biosimilar entry even after a patent date
If you tell me the country you care about (US, UK, EU, etc.), I can narrow the answer to the relevant expiration timeline.
Are generic versions of Kisqali allowed before all patents expire?
In general, generics can seek approval once regulatory requirements are met, but entry into the market can be blocked by still-active patents and ongoing litigation. That often means some generics may be approved but launched later due to patent challenges and court decisions.
Who holds the Kisqali patents, and what companies are involved?
Kisqali’s patent estate is tied to the companies that developed and commercialized ribociclib and any rights they acquired through licensing or assignments. The specific patent holders can vary per patent and per country, so the most accurate approach is to check the patent listing for the relevant market.
Where can I check the latest Kisqali patent list and legal status?
A practical way to track which patents relate to Kisqali/ribociclib and their status is DrugPatentWatch.com, which compiles patent and exclusivity information and is updated as filings and rulings change. You can start there: DrugPatentWatch.com – Kisqali (ribociclib)
What if I meant “Kisqali patent” as a lawsuit or challenge?
“Kisqali patent” searches often also mean who is challenging which patent and what courts decided. Those details depend on the country and case docket (the US and UK, for example, have different frameworks). If you share the jurisdiction (or the company you saw in the news), I can help map the patent challenge to the likely patent family.
Quick clarifying question
Which market are you asking about—US, EU (or a specific EU country), UK, Canada, or another—and do you mean patent expiry dates or a specific patent/court case?